Star Rating for Biosimilars Act
Bill journey · stage 1 of 5
Just introduced
What it doesSummary introduced in house (Oct 8, 2019)
Star Rating for Biosimilars Act
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish quality measures regarding biosimilar biological products under the five-star performance rating system for Medicare Advantage plans. The measures must assess the level of access that plans provide to covered biosimilars, including with respect to formularies, cost-sharing, and utilization management.
The CMS must also incorporate such measures into similar rating systems for plans under the Medicare prescription drug benefit.
What just happenedOct 18, 2019
Sponsor introductory remarks on measure. (CR H8232)
Who’s behind it
- Introduced in HouseOct 8, 2019
- Oct 18, 2019IntroReferralB00100
Sponsor introductory remarks on measure. (CR H8232)
- Oct 9, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Oct 8, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Oct 8, 2019IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Oct 8, 2019IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Oct 8, 2019IntroReferralIntro-H
Introduced in House
- Oct 8, 2019IntroReferral1000
Introduced in House